Skip to navigation


Mirati Therapeutics is a targeted oncology company developing therapeutics for precisely defined patient populations. The Mirati team is using a blueprint proven by their prior work for developing potential breakthrough therapies with accelerated development paths. Mirati is currently advancing three drug candidates through clinical development for multiple oncology indications. Mirati trades on the NASDAQ under the ticker symbol “MRTX.”

Contact Investor Relations

Marcy Graham
VP, Investor Relations and Corporate Communications
Mirati Therapeutics
Jesse Baumgartner
Stern Investor Relations

Shareholder Information

Transfer Agent

P.O. BOX 30170
College Station, TX 77842-3170


Ernst & Young LLP
4370 La Jolla Village Drive, Suite 500
San Diego, CA 92122